Muscular dystrophy (MD) is a spectrum of genetic disorders characterized by muscle weakness that, in severe forms, can lead to loss of ambulation and early mortality. Treatments are needed that can…
Multiple sclerosis (MS), a chronic immune-mediated disease of the nervous system, is classified as a rare disease in China because of its low prevalence in that country. Traditionally, MS patients…
The treatment of Parkinson’s disease (PD) requires personalized care, a high degree of polypharmacy, and frequent adjustments to achieve symptom control throughout the disease course…
The treatment journey for multiple sclerosis (MS) patients in the United States continues to evolve; nearly 20 immunomodulatory disease-modifying therapies (DMTs) are now available to treat the…
Clarivate Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of AD…
Myasthenia gravis (MG) is a rare neuromuscular disorder commonly caused by autoantibodies targeting acetylcholine (ACh) receptors and therefore affecting neuromuscular synaptic transmission at the…
Numerous disease-modifying therapies (DMTs) have entered the multiple sclerosis (MS) disease landscape in recent years, and many of them are next-generation alternatives within existing classes…
Clarivate Epidemiology’s coverage of dementia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dementia for each country, as…
Roche / Genentech achieved a clinical and regulatory milestone with the approval of Ocrevus for the treatment of primary-progressive multiple sclerosis (PP-MS)—making it the first agent to…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key mild cognitive impairment disease patient populations, covering 171…
Clarivate Epidemiology’s coverage of mild cognitive impairment (MCI) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Levodopa-induced dyskinesia (LID) is a complication stemming from the long-term use of levodopa to treat Parkinson’s disease (PD); it causes abnormal involuntary movements. Surveyed neurologists…
Clarivate Epidemiology’s coverage of Friedreich’s ataxia comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Epilepsy is a heterogeneous condition requiring individualized treatment, especially for patients who are persistently refractory to treatment. Neurologists consider many factors when selecting…